Stockwinners Market Radar for August 15, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:31 EDT South Carolina jury awards $63.4M to Johnson & Johnson asbestos victim - The company states: "A South Carolina jury has sided with a cancer patient who sued pharmaceutical giant Johnson & Johnson saying use of the company's iconic Baby Powder caused his lung cancer. Jurors awarded Michael Perry and his family $32.6 million in compensatory damages and another $30.7 million in punitive damages. Along with Johnson & Johnson, the jury also found co-defendant American International Industries negligent and liable in the case. Mr. Perry was diagnosed with mesothelioma, a terminal cancer exclusively caused by exposure to asbestos, in July 2023. He used the company's powder every day because he was allergic to deodorants."

20:24 EDT Lotus Technology provides driving solutions for Lynk's first all-electric sedan - Lotus Technology announced that its intelligent driving arm, Lotus Robotics, has provided intelligent driving solutions to Lynk&Co, a global leading automaker with operations across Europe and Asia. This collaboration marks a significant milestone in the commercialization of the Company's advanced technology capabilities.

19:50 EDT Eightco Holdings Inc trading halted, news pending

18:07 EDT DaVita exec Waters sells 7,857 common shares - In a regulatory filing, DaVita chief legal and public affairs officer Kathleen Alyce Waters disclosed the sale of 7,857 common shares of the company on August 13 at a price of $146.2093 per share.

17:54 EDT Southwest shareholder Artisan Partners issues statement on board candidates - Southwest shareholder Artisan Partners, whose discretionary investment management clients collectively hold more than 10.8 million shares of Southwest, or roughly 1.8% of the company's outstanding shares, issued a statement regarding director candidates for the Board of Southwest Airlines. Highlights include: "We have reviewed the biographies of the director nominees proposed by Elliott Investment...We believe the Elliott nominees would bring a wealth of experience to the Southwest board. These nominees would add several capabilities the board is currently lacking, including a number of independent directors with former airline executive experience from across a range of business models and geographies. The current Southwest board is simply not a credible alternative to this slate of directors...The current board has overseen a management team that has delivered continually deteriorating financial performance over the short, medium and long term...We urge the board to work with Elliott to immediately bring on all or substantially all of the proposed nominees who can then chart a new course with a new Chairman and CEO. If it will not, we will vote for the Elliott nominees should an extraordinary shareholder meeting be called..."

17:30 EDT Winnebago raises quarterly dividend to 34c per share from 31c - The dividend is payable on September 25, 2024, to common stockholders of record at the close of business on September 11, 2024.

17:22 EDT Lockheed Martin awarded $129.98M Air Force contract modification - Lockheed Martin has been awarded a $129.98M modification to a previously awarded contract to procure tooling and test equipment needed to increase production quantities of Joint Air-to-Surface Standoff Missile and Long-Range Anti-Ship Missile. Work is expected to be completed by December 15, 2027. The Air Force Life Cycle Management Center is the contracting activity.

17:18 EDT Keros Therapeutics director sells $11.0M in common stock - In a regulatory filing, Keros Therapeutics disclosed that its director Carl Gordon sold 250K shares of common stock on August 13th in a total transaction size of $11.0M.

17:05 EDT AptarGroup's nasal unidose system to deliver neffy alllergy treatments - AptarGroup's Unidose Liquid System is the delivery system approved with neffy - epinephrine nasal spray -, the first and only needle-free treatment approved by the FDA for the emergency treatment of patients with allergic reactions Type I, including anaphylaxis. This marks the first regulatory approval worldwide for nasally-delivered epinephrine. Aptar's Unidose is a single-use, ready-to-use, one-step nasal delivery system used to administer neffy to a patient during a severe allergic reaction. During such an event, the patient, healthcare professional, caregiver or user presses a small plunger on the bottom of the nasal spray system to release the drug in a single spray into the nostril. This novel treatment for severe allergic reaction is an example of a Combination Product submission, and benefited from Aptar Pharma's Services offering, a comprehensive portfolio of stage-specific development packages.

16:52 EDT Genius Group announces 1-for-10 reverse stock split Effective August 16 - Genius Group announced a 1-for-10 reverse stock split effective August 16, consolidating every 10 shares into 1 share. The company's common stock will trade on a post-split basis under the same symbol 'GNS' on NYSE American. The primary goal of the reverse stock split is to increase the per share market price of the Company's ordinary shares to meet the minimum per share price requirement for continued listing on the NYSE. Shares of the company's common stock will be assigned a new CUSIP number (Y3005A117) and are expected to begin trading on a split-adjusted basis on Friday, August 16. The ordinary shares issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not decrease the number of authorized ordinary shares or otherwise affect the par value of the ordinary shares. Every ten shares of common stock that may be purchased pursuant to the exercise of warrants prior to the effective time represent one share of common stock that may be purchased pursuant to such warrants following the effective time.

16:44 EDT Gates drops 3% to $16.61 after 20M share secondary for Blackstone affiliates

16:39 EDT Healthcare AI Acquisition signs merger agreement with Leading Group Ltd. - Healthcare AI Acquisition, or HAIA, and Leading Group Limited, a licensed digital insurance broker operating in the Insurance Services segment in China as an Insurance Channel Specialist, have entered into a definitive business combination agreement where HAIA and Leading will enter a series of merger transactions resulting in Leading as the surviving entity of the combined entity. Upon consummation, the parties intend to list the combined company on Nasdaq. The combined company will continue to be led by Leading's senior management team. Leading's digital insurance brokerage license and integrated marketing services helps insurance carriers to target and acquire customers at greater scale. The transaction values Leading at approximately $430M.HAIA and Leading intend to raise an additional private placement financing of $50M. Upon closing of the proposed transaction, Leading's shareholders will retain a majority of the outstanding shares of the combined company and Leading will designate a majority of the directors for the combined company board of directors. Leading expects to use the proceeds from the Proposed Transaction to accelerate the organic growth trajectory of the business in the China market. The transaction is expected to be completed in Q4, subject to, among other things, approval by the shareholders of Leading and HAIA, and the satisfaction of the other customary closing conditions, including the receipt of certain regulatory approvals.

16:38 EDT Abercrombie & Fitch partners with Haddad Brands on new distribution for kids - Abercrombie & Fitch announced a new partnership with Haddad Brands to expand the global reach of its Abercrombie kids brand. Within the agreement, A&F Co. will continue to design, produce and sell Abercrombie kids in its owned-and-operated channels as it does today. The company's partnership with Haddad Brands will focus on creating new distribution channels for the brand and growing the product line by adding infant and toddler categories to the existing assortment for 5-14-year-olds. The Fall/Back to School 2025 season of Abercrombie kids will be available in Haddad Brands' showrooms globally in September.

16:33 EDT Intel recommends stockholders reject 'mini-tender offer' by Tutanota - Intel said it recently learned of an unsolicited "mini-tender offer" made by Tutanota LLC to Intel stockholders to purchase up to 1 million shares of Intel common stock at $34 per share. The offer price of $34 per share is conditioned on, among other things, the closing price per share of Intel's common stock exceeding $34 per share on the last trading day before the offer expires. Unless this condition is waived by Tutanota, Intel stockholders who tender their shares in the offer will receive a below-market price. Tutanota can extend the offer for successive periods of 45 to 180 days, in which case payment would be delayed beyond the scheduled expiration date of Wednesday, Sept. 4, 2024. "This proposal is not in the best interests of Intel stockholders, and the company recommends that stockholders do not tender their shares in response to Tutanota's offer," Intel said. "In addition to offering below-market price, the offer is subject to numerous additional conditions, including Tutanota obtaining financing for the offer. There is no guarantee the conditions of the offer will be satisfied. Stockholders who have already tendered their shares may withdraw them at any time prior to the expiration of the offer, which is currently scheduled for 5 p.m. EDT, Wednesday, Sept. 4, 2024 (but which can be extended by Tutanota), by providing notice in the manner described in the Tutanota offering documents. Intel does not endorse Tutanota's mini-tender offer and is not affiliated or associated in any way with Tutanota, its mini-tender offer or the offer documentation."

16:32 EDT ResMed adds Becton Dickinson's CFO Christopher DelOrefice to board - ResMed (RMD) announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed's regularly scheduled board meeting on August 15 and will stand for re-election with the rest of ResMed's directors at its annual meeting on November 21 . Mr. DelOrefice has also been appointed as a member of ResMed's board audit committee. DelOrefice currently serves as executive vice president and chief financial officer CFO of Becton, Dickinson (BDX) and Company BD and brings over 30 years of audit, finance, and strategic expertise to augment and strengthen ResMed's diverse board. Before joining BD in September 2021, DelOrefice served in many roles at Johnson & Johnson (J&J), including most recently as vice president of investor relations and previously as CFO of J&J's consumer and medical device business segments for North America, along with roles in finance leadership for supply chain, corporate mergers and acquisitions, consumer research and development, and business development for J&J's North America pharmaceutical business. Before J&J, DelOrefice held positions of increasing responsibility in accounting, global audit, and financial reporting at AstraZeneca, AET Films, and Ametek.

16:31 EDT Incyte says Tafasitamab pivotal trial meets primary endpoint - Incyte announced positive topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide and rituximab compared to lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma. The trial met its primary endpoint of progression free survival by investigator assessment in FL. It also met key secondary endpoints of PFS in the overall population by investigator assessment as well as the positron-emission tomography-complete response rate in the FDG-avid FL population. In addition, the secondary endpoint of PFS results by blinded independent review are consistent with investigator based PFS results. No new safety signals with tafasitamab were observed. "While many patients with follicular lymphoma initially benefit from first-line treatment, relapse of the disease is common, underscoring the need for additional therapies," said Steven Stein, M.D., Chief Medical Officer, Incyte. "These results demonstrate the potential of tafasitamab added to the standard of care to be a meaningful new treatment option for patients with FL whose disease has progressed after at least one prior therapy."

16:24 EDT Portillo's jumps 3% to $12.19 after CNBC report of activist stake

16:22 EDT MDU Resources raises quarterly dividend 4% to 13c per share - The board of directors of MDU Resources Group has increased the quarterly dividend on the company's common stock to 13c per share, for an annualized dividend of 52c per share. This represents a 4% increase over the previous quarterly dividend of 12.5 cents per share. The board continues to target a long-term dividend payout ratio of 60% to 70% of regulated energy delivery earnings. The dividend is payable Oct. 1 to stockholders of record Sept. 12.

16:21 EDT MDU Resources raises quarterly dividend 4% to 13c per share - The board of directors of MDU Resources Group has increased the quarterly dividend on the company's common stock to 13c per share, for an annualized dividend of 52c per share. This represents a 4% increase over the previous quarterly dividend of 12.5 cents per share. The board continues to target a long-term dividend payout ratio of 60% to 70% of regulated energy delivery earnings.

16:19 EDT Lead Real Estate receives noncompliance notification - Lead Real Estate announced that the company received a written notification from Nasdaq on August 12 notifying the company that it is not in compliance with the minimum market value of publicly held shares requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq Global Market.

16:16 EDT Hawaiian rallies following agreement with DOJ to extend merger review - Alaska Air (AL) and Hawaiian Holdings (HA) disclosed earlier that they agreed with the Department of Justice to further extend the merger review period until 12:01 a. m. Eastern Time on August 20. "Alaska and Hawaiian continue to cooperate with the DOJ in this review process," the companies said in a regulatory filing. Shares of Alaska Air closed Thursday up 2% to $35.30 while Hawaiian closed up 10% to $16.46.

16:15 EDT CACI awarded $239M order from U.S. Army - CACI International "announced that it has been awarded a six-year expertise task order valued at up to $239 million to provide intelligence analysis and operations to U.S. Army Europe and Africa."

16:15 EDT Healthcare AI Acquisition Corp trading halted, news pending

16:11 EDT Verra Mobility CFO Conti sells 25,000 class A shares - In a regulatory filing, Verra Mobility CFO Craig Conti disclosed the sale of 25,000 class A common shares of the company on August 13 at a price of $26.9164 per share.

16:08 EDT Allurion Technologies receives continued listing standards notice from NYSE - Allurion Technologies announced that it received written notice from the New York Stock Exchange that it is not in compliance with the NYSE's continued listing standards because the average closing price of the company's common stock per the Notice was less than $1.00 per share over the consecutive 30 trading-day period ended August 8, 2024. The Notice does not result in the immediate delisting of the company's common stock from the NYSE. In accordance with applicable NYSE rules, the company plans to timely notify the NYSE that it intends to cure the stock price deficiency and return to compliance with the applicable NYSE continued listing standards. The company can regain compliance at any time within a six-month cure period following its receipt of the Notice if, on the last trading day of any calendar month during such cure period, the company has both: (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of the applicable calendar month. The company intends to remain listed on the NYSE and is considering all available options to regain compliance with the NYSE's continued listing standards, including, but not limited to, a reverse stock split, subject to stockholder approval. The NYSE rules provide for an extension to the six-month cure period if the action required to cure the price condition requires stockholder approval, in which case, the action needs to be approved by no later than the company's next annual stockholder's meeting and implemented promptly thereafter.

16:05 EDT Planet Labs to launch first hyperspectral satellite, Tanager-1 - Planet Labs PBC announced that its first hyperspectral satellite, Tanager-1, along with 36 SuperDoves will launch on the Transporter-11 Rideshare mission with SpaceX on Friday, August 16, 2024 from Vandenberg Space Force Base in California. Tanager-1 will expand Planet's capabilities by adding more than 400 spectral bands of data, capturing phenomena that are invisible to the human eye. Tanager-1 is made possible by the Carbon Mapper Coalition, a philanthropically-funded effort to develop and deploy industry-leading hyperspectral satellites designed to detect and track methane and CO2 super-emitters at a level of granularity that can support direct mitigation action. Tanager-1 combines Planet's cutting-edge agile aerospace and smallsat bus technology with the state-of-the-art imaging spectrometer design developed at NASA's Jet Propulsion Laboratory.

16:02 EDT Despegar sells DMC BDExperience to World2Meet - Despegar.com announced that it has formed a strategic alliance with World2Meet, the travel division of Iberostar Group, a Spain-based global tourism company. Under the alliance's agreement, World2Meet has acquired Despegar's Destination Management Company BDExperience effective August 1, 2024, and will operate as a preferred partner to Despegar for the provision of destination services in Mexico and the Dominican Republic. In line with Despegar's focus on key long-term growth strategies, improving operational efficiency and maximizing return on capital, the divestiture of DMC enables the Company to better concentrate resources on its core business and further strengthen its organic growth profile.

15:34 EDT Barings Corporate Investors increases quarterly dividend 2.6% to 40c per share - The board of trustees declared a quarterly dividend of 40c per share, payable on September 13 to shareholders of record on August 26. This represents an increase of 1c per share or 2.6% over the previous dividend of 39c per share.

13:55 EDT Abbott announces implantation of AVEIR DR pacemaker system in Canada - Abbott announced that the AVEIR dual chamber leadless pacemaker system, a dual chamber leadless pacemaker system that treats people with abnormal or slow heart rhythms, has been implanted for the first time at the Montreal Heart Institute, in Montreal, Quebec and Foothills Medical Centre in Calgary, Alberta.

13:29 EDT Moringa Acquisition Corp trading halted, volatility trading pause

13:10 EDT Paramount up 6% to $10.84 after Bloomberg report of Bronfman offer

13:04 EDT TC Biopharm regains compliance with Nasdaq listing rule - TC BioPharm announced that the Company has regained compliance with the Nasdaq Stock Market Listing Rule 5550(b) which will maintain the listing of the Company's American depositary shares on the Nasdaq Global Select Market. On May 24, 2024, the Company received written notification from the listing qualifications staff of the Nasdaq Stock Market, indicating that the Company was not in compliance with the Minimum Stockholders' Equity Requirement, as of March 31, 2024. This letter indicated that while Nasdaq estimates the Company is currently in compliance with the Minimum Stockholders' Equity Requirement it notes that based on the historical burn rate, without a significant transaction, the Company will not be in compliance as of the next period ending June 30, 2024. On August 1, 2024, the Company received written notification from Nasdaq that the hearing panel granted the Company's request to continue its listing on Nasdaq subject to compliance with the Minimum Stockholders' Equity Requirement on or before August 15, 2024. The Company believes that due to the closing of the transactions contemplated by the Purchase Agreement it is now in compliance with the Minimum Stockholders' Equity Requirement.

12:40 EDT EA's 'Dragon Age: The Veilguard' releases October 31, 2024 - Electronic Arts (EA) said that its upcoming role-playing game "Dragon Age: The Veilguard" will release October 31, 2024 for PC, PlayStation 5 (SONY), and Xbox Series X/S (MSFT). Reference Link

12:01 EDT Seritage Growth Properties rises 15.4% - Seritage Growth Properties is up 15.4%, or 57c to $4.27.

12:00 EDT Spruce Power Holding falls -8.5% - Spruce Power Holding is down -8.5%, or -28c to $3.06.

12:00 EDT Spire Global falls -29.2% - Spire Global is down -29.2%, or -$2.97 to $7.19.

11:39 EDT ZK International achieves Nasdaq compliance with filing requirements - On February 20, 2024, ZK International was notified by Nasdaq Staff that the Company no longer meet the periodic filing requirements under Listing Rule 5250(c)(1) due to a delayed filing of our annual report on Form 20-F for the year ended December 31, 2023. We are pleased to report that, based on the timely filing of our annual report on August 13, 2024, Nasdaq Staff has confirmed that ZK International is now in full compliance with the Rule. Accordingly, this matter is now officially closed.

11:10 EDT HNR Acquisition increases electrical capacity - HNR Acquisition announces key infrastructure improvements and upgrades to the electrical systems that will increase capacity for current needs and future growth, and enhance reliability of overall system which will provide consistency in performance and production. The field has three water stations to service the major sections of the water flood operations. The Russell Turner Water Station had low capacity and unreliable performance. The Company has assessed the electrical system and is in process of making upgrades of: Replacing and upgrading the transformer to a new reliable transformer. The replacement transformer will double the current capacity, which will satisfy current needs and provide capacity for our growth and expansion plans. The improvements will provide a constant electrical output and service which is better suited for all the downstream electronics, and minimize downtime caused by storms and other occurrences. Upgrading the lightning protection to minimize impacts of storms and protect the electrical equipment on the system Upgrading the horizonal pump, which is used to inject water, will greatly enhance our waterflood operations. The pump and related electronics have damage from past storms and issues. Accordingly, we are replacing with an upgraded horizonal pump and related electronics.

11:07 EDT Mattel announces multi-brand collaboration celebrating Barbie fashion - Mattel announced a multi-brand collaboration between the iconic Barbie brand and five female-led Canadian companies. Timed to the 65th anniversary of Barbie, the collection highlights the impact of Barbie through the decades with a unique design lens from each brand. As a collaborative effort, each Canadian brand - Hilary MacMillan, ai, Paris Jewellers Canada, Cheekbone Beauty and Sol Kyst - worked seamlessly together to design and develop eight cohesive looks, featuring over 100 products, inspired by iconic Barbie dolls over the past six decades. All participating brands and pieces will launch simultaneously on August 15 at 11 A.M. E.S.T., with integrated web interfaces, which allow consumers to shop each brand hyperlinked together, allowing seamless consumer experience.

11:03 EDT Box appoints Tricia Gellman as CMO - Box (BOX) announced the appointment of Tricia Gellman as Chief Marketing Officer. As CMO, Gellman will help accelerate the company's path to $2 billion in revenue and its evolution as an Intelligent Content Management platform, delivering AI-powered collaboration, workflow automation, and security. Gellman brings over two decades of experience driving growth for leading technology companies, including Salesforce (CRM) and Adobe (ADBE).

11:00 EDT Asure Software acquires HireClick, terms not disclosed - Asure has acquired HireClick, a hiring solution designed to streamline the recruitment process for small and mid-sized businesses. This strategic acquisition reinforces Asure's commitment to delivering comprehensive, user-friendly tools that simplify people management. HireClick's all-in-one hiring solution offers a seamless experience for creating job descriptions, posting to national job boards, tracking applicants, and hiring top talent through a streamlined and intuitive process. The solution includes a personalized careers website, mobile-friendly job applications, and built-in AI support to craft effective job descriptions. With an intuitive dashboard, employers can easily view, filter, and track applications, as well as communicate with candidates throughout the hiring process.

10:14 EDT B Riley Financial trading resumes

10:09 EDT B Riley Financial trading halted, volatility trading pause

10:01 EDT HII unit awarded $30M task order - HII announced that its Mission Technologies division was awarded a task order to support the U.S. Air Force's efforts to recapitalize and sustain its fleet of presidential and executive aircraft. The contract is valued at over $30M. An HII team in Dayton, Ohio, will perform a broad set of tasks to enhance the reliability and supportability of aircraft and aircraft systems under the contract, which will be administered by the U.S Air Force Life Cycle Management Center's Presidential and Executive Airpower Directorate. The directorate is responsible for planning and executing all life-cycle activities related to the recapitalization of Air Force One and E-4B aircraft, and sustainment of the current Air Force One, E-4B, C-12, C-32, C-37, and C-40 aircraft.

10:00 EDT Seritage Growth Properties rises 14.9% - Seritage Growth Properties is up 14.9%, or 55c to $4.25.

10:00 EDT Greenlane Holdings trading resumes

10:00 EDT Spire Global falls -30.9% - Spire Global is down -30.9%, or -$3.14 to $7.02.

09:48 EDT GCT Semiconductor falls -7.5% - GCT Semiconductor is down -7.5%, or -27c to $3.33.

09:47 EDT Spire Global falls -34.0% - Spire Global is down -34.0%, or -$3.45 to $6.71.

09:47 EDT Warby Parker rises 9.9% - Warby Parker is up 9.9%, or $1.26 to $14.05.

09:41 EDT Bolt Projects Holdings Inc trading resumes

09:34 EDT Singlepoint Inc trading halted, volatility trading pause

09:29 EDT Xylo says ParaZero receives order for 50 drone safety systems - Xylo Technologies (XYLO) announced that ParaZero Technologies (PRZO), 18.68% owned by Xylo, initiated a partnership with a leading Tier 1 defense OEM company to adapt and integrate its advanced drone safety system for operational military and medical mission use. ParaZero received an initial order as part of a wider collaboration that aims to enhance the efficiency and safety of medical field mission's deliveries, particularly in critical and remote areas. In the initial phase, ParaZero will provide 50 systems to the customer for testing, during which time ParaZero will develop and validate the necessary adaptations for the medical delivery system. Upon successful completion of the testing phase, the customer plans to purchase additional hundreds of systems for a pilot program. These stages are expected to be completed by the end of 2024, after which the adapted systems will enter commercial production for operational use by this customer and other customers. ParaZero's target is to develop a scalable, cost-effective mass production system that can be deployed widely, ensuring that medical deliveries are safer, faster, and more reliable.

09:11 EDT Aligos Therapeutics announces 1-for-25 reverse stock split - Aligos Therapeutics announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. The reverse stock split will become effective at 12:01 am ET on Monday, August 19, 2024. The Company's common stock is expected begin trading on the Nasdaq Capital Market under the same symbol on a split-adjusted basis at the market open on August 19, 2024 with the new CUSIP number 01626L 204.

09:10 EDT Edible Garden launches VitaminWhey.com e-commerce site - Edible Garden announced the launch of the VitaminWhey.com e-commerce site for the Company's Vitamin Whey line of whey and plant protein powders under the Vitamin Whey and Vitamin Way brands.

09:09 EDT LPL Financial: Wealthstead joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Jason Walker, Vladimir Nikitenko, H. Scott Braswell, Rosty Tkachenko and John Hydrick, have joined LPL Financial's broker-dealer, RIA and custodial platforms, aligned with existing firm Integrated Financial Group. They reported serving approximately $615 million in advisory, brokerage and retirement plan assets and join LPL from Lincoln, now part of Osaic. The Atlanta-based advisors are longtime colleagues who branched off to create a new practice, Wealthstead Financial Advisors. Led by Managing Partner Jason Walker, an Army veteran and graduate of the U.S. Military Academy at West Point, the Wealthstead team offers comprehensive financial planning services and investment advice, with a focus on retirement income planning and portfolio management. Their business primarily grew out of the nonprofit market and has a strong track record of helping clients on their path to financial success. Now, their diverse client base includes mass affluent families, executives and business owners.

09:08 EDT SolarMax expands U.S. footprint with new solar project in California - SolarMax Technology signed a non-binding term sheet for a significant new commercial solar project in California. The project, a major mall in the San Jose area, represents another step forward in SolarMax' ongoing strategy to expand its solar development capabilities in the US commercial market. The proposed California project is to include the development and management of a 4.17 megawatt photovoltaic solar power plant and a 2.0 MW energy storage system. As part of the project, SolarMax will also oversee the replacement of the mall's roof to support the new solar infrastructure.

09:07 EDT Bitdeer announces proposed offering of $150M convertible notes - Bitdeer Technologies announced a proposed registered underwritten public offering by the Company of $150,000,000 aggregate principal amount of its convertible senior notes due 2029, subject to market and other conditions. The Company also intends to grant the underwriters in the Offering a 30-day option to purchase up to an additional $22,500,000 aggregate principal amount of Notes on the same terms and conditions, solely to cover over-allotments. The Notes will be senior, unsecured obligations of the Company. The Notes will mature on August 15, 2029, unless earlier converted, redeemed or repurchased. Holders may convert their notes at their option prior to the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, the Company will pay or deliver to such converting holders, as the case may be, cash, Class A ordinary shares, par value US$0.0000001 per share, of the Company or a combination of cash and Class A ordinary shares, at its election. The interest rate, initial conversion rate and certain other terms of the Notes will be determined at the time of pricing of the Notes. The Company intends to use the net proceeds from the Offering for datacenter expansion, ASIC based mining rig development as well as working capital and other general corporate purposes. BTIG is acting as book-running manager for the Offering. A.G.P./Alliance Global Partners is acting as co-manager for the Offering.

09:06 EDT Montana Technologies Corp. signs MOU with Tenx Investment - Montana Technologies Corporation announces the signing of a Memorandum of Understanding (MOU) with TenX Investment in Energy Enterprises & Management Co. to address water security and energy efficiency opportunities in the United Arab Emirates. The collaboration between Montana Technologies and TenX aims to leverage AirJoule(R)'s cutting-edge technology to generate pure distilled water from air and reduce energy consumption for air conditioning, significantly enhancing water security and energy sustainability in the UAE. The Company and TenX will explore options to deploy AirJoule(R) units with initial installations focusing on critical infrastructure and community water needs.

09:05 EDT Siga Technologies falls 37% to $7.58 after mpox study failure

09:05 EDT Blackstone acquires majority stake in M3, terms undisclosed - M3 announced it has signed a definitive agreement for a majority investment from Blackstone Growth and affiliated funds. The investment will help to accelerate the company's growth by enhancing new product expansion and supporting the adoption of M3's software. AAHOA, representing nearly 20,000 hotel owners and 60% of hotels across the United States, will make its first ever strategic investment alongside Blackstone. Terms of the transaction were not disclosed.

09:01 EDT Deere sees FY24 net operating cash flow $6B-$6.5B - Sees FY24 effective tax rate 23%-25%. Sees R&D expenses up slightly. Sees CapEx about $1.8B. Comments taken from Q3 earnings conference call presentation slides.

08:56 EDT Deere provides industry outlook for FY24 - For agriculture & turf: Sees U.S. & Canada Large Ag down about 15%; Sees U.S. & Canada Small Ag & Turf down about 10%; Sees Europe down about 15%; Sees South America down 15%-20%; Sees Asia down moderately. For Construction & Forestry: Sees U.S. & Canada construction equipment down 5%-10%; Sees U.S. & Canada compact construction equipment flat to down 5%; Sees global forestry down about 10%; Sees global roadbuilding flat to down 5%.

08:47 EDT Deere sees FY24 Production & Precision Ag net sales down 20%-25% - Sees FY24 Small Ag & Turf net sales down 20%-25%. Sees FY24 Construction & Forestry net sales down 10%-15%. Fiscal-year 2024 net income attributable to Deere & Company for the financial services operations is forecasted to be approximately $720 million. Results are expected to be higher than fiscal year 2023 due to income earned on higher average portfolio balances, partially offset by a higher provision for credit losses and less-favorable financing spreads. A correction of the accounting treatment for financing incentives offered to John Deere dealers impacted 2023 financial results. The cumulative effect of this correction, $173 million pretax was recorded in the second quarter of 2023.

08:41 EDT Skyward Specialty Insurance strengthens regional contract surety teams - Skyward Specialty Insurance Group announced the strategic addition of key surety professionals as it continues to strengthen its regional Contract Surety teams. In its Northeast region, Skyward Specialty welcomed Gregg Callahan as regional vice president in New England. Callahan spent the last 27 years at Liberty Mutual Insurance specializing in Contract Surety. The Company has hired Larry Mastalski as regional vice president in the Texas and Midwest territories. Sam Allison has joined Skyward Specialty as assistant regional vice president in Texas. Sean Fallows was hired as regional assistant vice president to develop the Company's western contract surety portfolio. In addition to these impressive leaders, the Company has added two new underwriters to fortify its underwriting bench strength in select regions. Joe Waynauskas joins as senior underwriter in the north-central region, and Joe Michalewsky, ASFB, joins the Northeast region as an underwriter.

08:38 EDT Comstock completes testing to validate renewable fuel yields - Comstock and its subsidiary, Comstock Fuels announced completion of testing to validate renewable fuel conversion yields of up to 125 gallons per dry ton of woody biomass on a gasoline gallon equivalent basis. Comstock Fuels offers advanced lignocellulosic biomass refining solutions that are now proven to produce renewable fuels at market-leading yields and carbon intensities, including ethanol, gasoline, renewable diesel, and sustainable aviation fuel. Comstock Fuels' processes are designed to be robust and highly-scalable to maximize optionality and throughput. These processes rely on modular integrations of mature process technologies with the flexibility to accept and fractionate all known species of woody biomass into intermediates for direct conversion into renewable fuels, including Comstock Fuels' proprietary hydrodeoxygenated Bioleum Oil, which is qualified today for use in producing advanced renewable fuels under ASTM D1655. Comstock Fuels' processes additionally incorporate variations of mature and widely-used hydroprocessing and cracking technologies to directly produce SAF and other advanced renewable fuels under D7566, subject to applicable approvals. Comstock Fuels' yields and carbon intensities generally vary based on feedstock selection and composition, site selection, and other factors. However, Comstock Fuels has now validated a baseline yield of 125 GGE and carbon intensity of 15 with a mixture of hardwood feedstock species, without emissions capture and conversion. Comstock Fuels is also currently evaluating modular integration of mature processes to capture and convert its biogenic carbon emissions into additional Bioleum derived fuels, thereby enabling increased yields approaching 150 GGE, or more than about 80% of the theoretical maximum yield from woody biomass.

08:37 EDT Millicom announces extension of consent solicitations - Millicom International Cellular announced the extension of the period during which it will solicit consents from the holders of record on August 2, 2024 of its 6.625% Senior Notes due 2026, 5.125% Senior Notes due 2028 6.250% Senior Notes due 2029, 4.500% Senior Notes due 2031 and 7.375% Senior Notes due 2032 to amend certain provisions of the indentures governing the Notes. The consent solicitations for each series of Notes are being made solely on the terms and subject to the conditions set forth in the consent solicitation statement dated August 5, 2024, as amended by this announcement. Millicom hereby amends the Consent Solicitation Statement by extending the period during which it will solicit Consents to 5:00 p.m., New York City time, on August 23, 2024, unless further extended. Except as specifically provided herein, Millicom does not intend to, nor shall it, modify the Consent Solicitation Statement in any other manner.

08:35 EDT Nuvve and WISE EV team on public high-speed EV charging infrastructure - Electric vehicle drivers will soon have greater access to convenient public high-speed EV charging stations. Nuvve Holding and WISE EV have partnered to bring EV charging to more than 100 high-traffic locations across the country. "We're making EV adoption even more attractive to those with range anxiety," said Gregory Poilasne, CEO of Nuvve. "These charging stations have added value because they will not only serve the immediate needs of EV drivers but also will provide essential grid services by integrating Nuvve's V2G technology, stabilizing the electric grid during peak usage times." "This collaboration is about more than just technology; it's about bringing together two companies with a shared vision to fill the void in EV charging deserts throughout the country," said Kevin Williams, President/CEO of WISE EV. "This collaboration is a significant step forward in our mission to build a more resilient and sustainable energy future. The partnership marks a pivotal moment for both companies as we expand the reach, accessibility and impact of their technologies, creating a network of public chargers that will make a real difference for both underserved consumers and businesses."

08:34 EDT Guardforce AI expands AIoT Robot Advertising in U.S. - Guardforce AI announced the expansion of its Artificial Intelligence of Things, AIoT, Robot Advertising business into the U.S. market, beginning with the initial deployment of over 200 robots in New York. This significant milestone is a key step in Guardforce AI's broader strategy to expand its advertising business. Additionally, the Company has completed the proof-of-concept for a decentralized spatial computing solution on its robots, which is expected to launch in late August.

08:29 EDT Lifeist Wellness chairman provides details on decision to sell CannMart - Chairmen Branden Spikes said, in part, "In response to inquiries from many of you, we wish to set forth the reasoning behind the strategic decision to divest Lifeist of CannMart via a sale to Simply Solventless Concentrates under the terms of the agreement set forth in our press release of June 25, 2024. The decision to sell CannMart is the result of careful consideration by the Lifeist Board with input from its advisors and is aimed at securing the near- and long-term viability and success of Lifeist for the benefit of all shareholders. As you all know, the regulatory framework under which Canadian public cannabis companies operate has proven to be prohibitively expensive for all public companies in the space in terms of ever being able to turn a profit. This experience has not been unique to Lifeist or CannMart: the vast majority of Canadian public cannabis companies, from the largest to the smallest, from generalists growing stadium-sized crops to specialists focused on extracts, distillates, beverages, and exotics, have been unable to turn a consistent profit. As a result, share prices across the entire sector have been in a long and grinding bear market for several years. The previously high-flying TSX Cannabis Index, after peaking in early 2021, was delisted in April 2023 after losing over 90% of its value. Success stories in the cannabis space have been few and far between, but SSC is clearly one of them. SSC have proven themselves capable of succeeding in an extremely challenging sector, returning profitable quarters repeatedly while growing their market. It is the considered position of the Board that the best chance of success for CannMart is as a part of SSC, and the best hope for Lifeist shareholders to enjoy capital appreciation on the value of the CannMart assets is similarly through their sale to SSC. Lifeist shareholders stand to benefit from this in four key ways: First and foremost, through the realization of direct value through the sale of CannMart to SSC: $500,000 payable upon the closing date. $1,500,000 plus applicable interest in a VTB loan, subject to adjustments as set forth in the share purchase agreement. $500,000 satisfied by the issuance of units, comprised of one common share and one-half purchase warrant to purchase one common share of SSC. SSC shall pay Lifeist 100% of the net revenue generated by the sale of 50% of existing inventory (presently estimated at $1,000,000 value), separate and in addition to any other fees. An earnout bonus of 20% of any revenue above $3,000,000 per quarter over the first 12 months. Second, through the divestiture of the consistent loss leader that CannMart has been and would otherwise continue to be for Lifeist under the presently applicable Canadian public cannabis company regulatory framework. This will remove the continued negative cash flow that the cannabis business has cost shareholders and give Lifeist its best chance at demonstrating positive cash flow. Third, through the opportunity for capital appreciation via the common shares and warrants that Lifeist will hold in SSC after the sale has been completed. It is worth noting that SSC shares have dramatically outperformed the sector as well as the broader market, rising nearly 50% just since the proposed CannMart transaction was announced on June 25th. Fourth, through the concentration of all resources on driving forward the success of Mikra Cellular Sciences, with no distractions in other sectors and ventures and substantially reduced costs as a result of that renewed singular focus. We are more confident than ever in Lifeist's roadmap to future cash flow positivity and profitability. The combination of this divestiture and several critical initiatives already underway at Mikra hold great promise for the realization of shareholder value in the near- and intermediate-term, and this proposed sale of CannMart is the key to opening the door to that future. We sincerely hope that shareholders will vote in favor of the proposed sale, and thus be positioned to benefit from its completion, and the survival and growth of your company."

08:16 EDT CNS Pharmaceuticals sees cash runway through 1Q25 - As of June 30, 2024, the Company had cash of approximately $1.5 million. Between June 30, 2024 and August 14, 2024, the Company has raised total gross proceeds of approximately $12.4 million of financing, and has sufficient cash to fund its operations through the first quarter of 2025. The Company expects to be able to release final topline data from its potentially pivotal trial of Berubicin in the first half of 2025.

08:13 EDT CMC Metals chairman John Bossio resigns - CMC is announcing changes to the Board of Directors. After 14 years of dedicated service on the Board, with the last 4 years as the role of Chairman, Mr. John Bossio has decided to resign from the Board to pursue personal activities. Mr. Bossio will remain as an Advisor to the Board. Mr. Bossio has been replaced by Mr. John Land as a Director of the Company.

08:10 EDT Tempest announces feedback form End-of-Phase 2 meeting with FDA for TPST-1120 - Tempest Therapeutics announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma. Key outcomes of the FDA meeting include: Agreement on Phase 3 study design, including the standard-of-care control arm and the primary and secondary study endpoints; Agreement on appropriateness of the current amezalpat dose and schedule for the Phase 3 study; Agreement on the Phase 3 statistical plan including a pre-specified early efficacy analysis that the company currently estimates could shorten the time to primary analysis by up to 8 months.

08:09 EDT Genetic Technologies announces global launch of geneType on EasyDNA platform - Genetic Technologies announces the global launch of the geneType Risk Assessment portfolio on our wholly owned EasyDNA platform currently selling in 42 countries, setting the stage for the potential significant expansion of the Company's current A$7.5m annual revenues. This expansion allows the Company to promote and sell its most powerful geneType innovation on its most profitable channel to realise more than 70% gross margin. This key step change in conjunction with the Company's structural reset will reduce cash burn to under A$200k per month from the previous A$800k, driving the Company towards its profitability target.

08:08 EDT ABM awarded NASPO ValuePoint contract for EV charging solutions - ABM announces it has recently been awarded a NASPO ValuePoint contract for electric vehicle charging infrastructure. This important contract authorizes ABM to offer its industry-leading, single-source EV charging infrastructure solutions to state and local government and educational entities across the nation more efficiently and cost-effectively. "We're honored to be awarded a NASPO ValuePoint contract which recognizes our growing position and leading technology in the evolving EV landscape," stated Mark Hawkinson, ABM's President of Technical Solutions. "We believe our ability to now offer state and local government and educational institutions nationwide access to our single-source turnkey EV infrastructure solutions will help drive EV adoption rates while at the same time providing these governments and organizations cost-effectiveness, sustainability, and reliability."

08:07 EDT Hoth Therapeutics and Aronnax sign master services agreement for HT-KIT - Hoth Therapeutics has entered into a Master Services Agreement with Aronnax for its HT-KIT cancer therapeutic. HT-KIT research to evaluate the efficacy of HT-KIT in cancerous and non-cancerous cells has demonstrated that HT-KIT effectively kills human mast cells that rely on signaling through the KIT receptor to survive. The effect of a single dose lasted for about two weeks, while reduced KIT expression lasted for 7 days. This result also demonstrated HT-KIT's potential to reduce KIT expression using GIST cells and kill within 48 and 72 hours along with lower KIT expression in AML cells over 72 hours. HT-KIT is being developed for the treatment of mast cell-derived cancers and anaphylaxis and previously received Orphan Drug Designation from FDA. This study will provide Hoth key metrics in both max dose and range finding elements which will help formulate its proposed clinical trial.

08:06 EDT Duolingo partners with Sony Music to add recordings to music course - Duolingo (DUOL) announced a partnership with Sony Music (SONY) that brings popular songs to its Music course. This new feature is designed to make learning music more fun and engaging by incorporating well-known songs into the curriculum. More than 60 recordings from Sony Music artists, like Dove Cameron, Hozier, Meghan Trainor, Whitney Houston, and more, are now available so learners can study the foundations of music and practice their music theory skills, such as reading music, understanding note lengths, and differentiating notes by sound, sight, and key on a digital mobile piano.

08:04 EDT FuelCell announces participation in World Brewing Congress - FuelCell Energy announced its participation in the World Brewing Congress, taking place August 17-20 in Minneapolis, Minn. The event will provide a platform for FuelCell Energy to showcase its innovative solutions for CO2 utilization and sustainability in the brewing, food, and agriculture industries. Countries and companies around the world are rushing to reduce their carbon footprints, particularly with respect to the energy, transportation, and heavy industry sectors. However, at the same time, there is a demand for a cleaner way of generating CO2. The certainty of supply and long-term pricing for CO2, especially in the food and beverage industry, is mission critical because CO2 provides the bubbles in beer, keeps steak fresh, helps process the sugar in dessert, and pH balances the water we drink. In fact, CO2 permeates the food chain and is a glue between manufacturers, processors, stores, restaurants, and the consumer. In recent years, there have been supply disruptions in the CO2 market for a variety of reasons - some temporary and others more lasting - that have made it harder for food and beverage companies to find the high-quality CO2 they need. Also, food and beverage companies are experiencing price spikes from industrial gas suppliers that directly impact food and beverage pricing. FuelCell Energy's technology enables food and beverage suppliers to eliminate these negative business challenges. FuelCell Energy's solution is also in step with the race for clean energy solutions to everyday problems. The company's patented molten carbonate fuel cell technology provides customers with three significant benefits from a single onsite system.

08:04 EDT Agilysys appoints Joe Youssef as chief commercial officer - Agilysys announced Joe Youssef will join the company as senior VP, sales, Americas and EMEA and chief commercial officer. Youssef is stepping into the executive role held by Don DeMarinis since January 2018. Youssef will officially begin his tenure at Agilysys on August 19.

08:01 EDT Oculis appoints Sharon Klier as CDO - Oculis Holding announced the appointment of Dr. Sharon Klier to the role of Chief Development Officer. In this key role, Dr. Klier will oversee and provide strategic leadership across the clinical development and operations of Oculis' robust ophthalmology pipeline. Before joining Oculis, she served as Chief Development Officer, Head of Ophthalmology at UNITY Biotechnology, where she played a key role in driving forward UNITY's pipeline.

07:52 EDT GeoVax shares jump after after Siga mpox study failure - Shares of Geovax Labs (GOVX) are moving higher after Siga Technologies (SIGA) announced topline results from a preliminary analysis of the PALM 007 study for the treatment of monkeypox virus. The National Institute of Allergy and Infectious Disease reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo with monkeypox, who were administered Siga's tecovirimat. In December 2023, GeoVax amended a previously executed license agreement with the National Institute of Allergy and Infectious Diseases to expand the company's commercial license to include mpox and smallpox as additional indications. GeoVax shares are up 19% in premarket trading to $3.86 while Siga is down 2% to $11.70.

07:49 EDT Gilat Satellite joins WAVE Consortium board - Gilat Satellite Networks announced its selection as a board member of the newly established Waveform Architecture for Virtualized Ecosystems Consortium. Gilat joins a distinguished group of board members committed to driving innovation in satellite communication networks through agile, scalable, and cost-effective infrastructure. Established in March 2024, the WAVE Consortium emerges at a critical juncture as the satellite communications industry aligns with the broader telecommunications sector. This alignment seeks to expand the reach and capabilities of satellite communications, meeting the ever-evolving demands for connectivity. Gilat's involvement with WAVE underscores its commitment to fostering an open, interoperable ecosystem that transcends traditional growth constraints. Gilat's Head of Research & Algorithms, Guy Levitas, and Chief Architecture Officer, Adi Adotler, will represent the company on the WAVE Consortium board.

07:47 EDT CureVac CFO Pierre Kemula to depart - After eight years as CureVac's CFO, Pierre Kemula will leave CureVac at the end of his contract term on October 31, 2024. A search for his succession is ongoing.

07:43 EDT LSI Industries: Production schedules, supply chain issues impacted Lighting - "Within the Lighting segment, we experienced generally stable demand conditions across most of our vertical markets in the fourth quarter," stated Clark. "In fiscal 2024, sales were 4% below prior year, with LSI outperforming the broader market, capturing share in select vertical markets. Operating income for the year increased 5% driven by the 200-basis point increase in gross margin. Recent trends continue as project quotation levels remain steady; however, the quote-to-order conversion period remains extended, particularly for larger project activity. Construction schedule changes persist due to non-lighting supply chain issues together with availability of skilled labor. With lighting installation occurring in the late-cycle phase of construction, we continue to incur high levels of production schedule changes to our backlog, given changes in project timing. Pricing for project quotations remains stable and we expect that trend to continue in the first quarter of fiscal 2025.

07:37 EDT Siga Technologies announces PALM 007 trial did not meet primary endpoint - The National Institutes of Health's, NIH, National Institute of Allergy and Infectious Diseases, NIAID, announced topline results from a preliminary analysis of the PALM 007 clinical trial. NIAID reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo with monkeypox, who were administered SIGA's tecovirimat, a highly targeted antiviral treatment, versus placebo. All patients in this study were hospitalized for the entire duration of treatment. This study was not a registration study conducted under an U.S. FDA Investigational New Drug Application.A meaningful improvement was observed in patients receiving tecovirimat whose symptoms began seven days or fewer before randomization and in those with severe or greater disease, defined by the World Health Organization (WHO) as having 100 or more skin lesions. While more analysis is required, the Company believes these data support further trials to assess the potential benefit of tecovirimat in those who present to medical care soon after symptoms and in those with severe disease.

07:36 EDT Kore Group appoints Ron Totton as CEO - Kore Group appointed Ron Totton to the role of President and CEO, after a period of leading the company on an interim basis.

07:35 EDT Bread Financial reports July net loss rate 8% vs 7.4% last year - Reports End-of-period credit card and other loans $ 17.659B vs $ 17.963B last year

07:29 EDT CureVac appoints Mehdi Shahidi to supervisory board - CureVac named clinical oncologist Mehdi Shahidi, M.D., as an independent director to the company's Supervisory Board. Dr. Shahidi replaces Ralf Clemens, who served on the Supervisory Board from March 2016 through September 2023. Shahidi is currently the CEO of Petalion Therapeutics, a UK-based biotechnology company developing targeted dendrimer therapies in oncology as well as a Venture Partner at Medicxi, a leading European life sciences investment firm. Shahidi's appointment takes effect at the CureVac SE level as of beginning of September 2024, with his appointment in regard to CureVac N.V. to be considered at the next Annual General Meeting in June 2025.

07:21 EDT Quince Therapeutics announces Phase 3 ATTeST trial for A-T evaluated in Lancet - Quince Therapeutics announced the online publication of data in The Lancet Neurology from its Phase 3 ATTeST or Ataxia-Telangiectasia Trial with the EryDex SysTem clinical trial evaluating the safety and efficacy of its lead asset, EryDex or dexamethasone sodium phosphate encapsulated in autologous erythrocytes , for the treatment of A-T. "The results of this study demonstrate the encouraging efficacy and safety profile of our lead asset, EryDex, for the treatment of patients with A-T, a rare pediatric disease with vast unmet need and no approved treatments," said Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer. "These findings provide us with additional confidence in our pivotal Phase 3 study of EryDex now underway with a primary analysis population comprised of patients with A-T experiencing the most rapid clinical decline - children ages six to nine - in addition to including participants who are ten years of age or older."

07:16 EDT Cellebrite announces redemption of all outstanding warrants - Cellebrite DI will redeem all of its warrants to purchase ordinary shares of the Company that remain outstanding at 5:00 p.m. New York City time on September 16, 2024 for a redemption price of $0.10 per Warrant. The Warrants include the outstanding public warrants to purchase Ordinary Shares issued pursuant to that certain Assignment, Assumption and Amended and Restated Warrant Agreement, dated on August 30, 2021, between the Company and Equiniti Trust Company, which were originally issued by TWC Tech Holdings II Corp. in connection with its initial public offering and subsequently assumed by the Company and converted into warrants to purchase Ordinary Shares of the Company as a result of the Company's business combination with TWC which was consummated on August 30, 2021 for a redemption price of $0.10 per Public Warrant and the outstanding private placement warrants to purchase Ordinary Shares originally issued by TWC in a private placement transaction under the Private Placement Warrants Purchase Agreement, dated as of September 10, 2020, by and between TWC and TWC Tech Holdings II, LLC, and converted into warrants to purchase Ordinary Shares of the Company as a result of the Business Combination, on the same terms as the outstanding Public Warrants. Equiniti serves as warrant agent with respect to the Warrants.

07:15 EDT Tilray launches new THC infused sparkling beverages, topicals - Tilray Brands announced the expansion of its Solei cannabis product lineup. With the positive receptivity from their first initial launch of beverages last summer of 2023, Solei has launched two additional infused sparkling beverages with a focus on lower THC, and dominant CBD and CBG cannabinoids that now come in Blood Orange and Dark Cherry.

07:14 EDT Abata Therapeutics announces equity investment from Bristol Myers - Abata Therapeutics has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis.

07:13 EDT Transcode Therapeutics announces Phase 1 trial initiation - TransCode Therapeutics announced initiation of its Phase 1 multicenter, open-label, clinical study of its lead therapeutic candidate, TTX-MC138. Two clinical trial sites have been activated with patient enrollment expected to begin during the current quarter. TransCode may activate a total of up to five clinical trial sites, all of which are expected to be activated this quarter.

07:12 EDT uniQure announces dosing of first patient in Phase I/IIa trial of AMT-191 - uniQure N.V. announced that the first patient has been dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease, a rare, inherited genetic disease. The Phase I/IIa study is a multi-center, open-label trial being conducted in the United States with two dose-escalating cohorts assessing the safety, tolerability and early signs of efficacy of AMT-191 in individuals with Fabry disease.

07:04 EDT GreenPower Motor to deliver five Type D BEASTs to California schools - GreenPower Motor Company announced it will deliver five Type D BEAST all-electric, purpose-built, zero-emission school buses to two school districts in California this week. Of the five BEASTs to be delivered this week, four will go to the Cutler-Orosi Joint Unified School District and the fifth to the Terra Bella Union Elementary School District. In addition to this week's deliveries, in the next few weeks GreenPower plans to deliver up to four more Type D BEAST all-electric, purpose-built, zero-emission school buses to California schools, and two BEASTs to schools in Oregon, with up to an additional 20 school buses expected to be delivered in California over the next 90 to 120 days.

06:51 EDT Tapestry says 'working expeditiously' to close Capri Holdings deal in 2024 - "On August 10, 2023, Tapestry (TPR) announced a definitive agreement to acquire Capri Holdings (CPRI), establishing a powerful global house of iconic luxury and fashion brands. Importantly, this transaction will bring significant benefits to the combined company's customers, employees, partners, and shareholders around the world. Further, the acquisition builds on Tapestry's track record as a consumer-centric brand-builder and disciplined operator and accelerates its strategic and financial growth agenda. On April 22, 2024, the Federal Trade Commission filed a lawsuit in an attempt to block the proposed acquisition. The company is confident in the merits and pro-competitive, pro-consumer nature of this transaction and looks forward to presenting its strong legal arguments in court, working expeditiously to close the transaction in calendar year 2024."

06:37 EDT Lockheed Martin, General Dynamics report strategic teaming agreement - Lockheed Martin (LMT) and General Dynamics (GD) announced this week the signing of a strategic teaming agreement for the production of solid rocket motors that will bring security and resiliency to a vital domestic supply chain. "Maintaining a robust and diverse supply chain for solid rocket motors is critical to advancing our 21st Century Security vision for a stronger, more resilient defense industrial base that keeps our customers around the globe ahead of emerging threats. This agreement enables Lockheed Martin and General Dynamics to ramp production of in-demand solutions more quickly going forward," said Tim Cahill, president of Lockheed Martin Missiles and Fire Control. Initial work will focus on the production of solid rocket motors for the Guided Multiple Launch Rocket System and will be performed at the General Dynamics facility in Camden, Arkansas starting in 2025. This project will be followed by a phased planning approach to transition to other products.

06:35 EDT BiomX announces 1-for-10 reverse stock split - BiomX announced that it intends to effect a one-for-ten reverse split of the company's common stock. The Common Stock will continue to trade on the NYSE American under the existing symbol "PHGE" and will begin trading on a split-adjusted basis when the market opens on August 26, 2024. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 09090D 301.

06:32 EDT Haemonetics announces full market release of Vascade MVP XL - Haemonetics announced the full market release of its Vascade MVP XL mid-bore venous closure system. The Vascade MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' Vascade portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.

06:03 EDT Faraday Future announces reverse stock split, authorized share reduction - Faraday Future intends to implement a reverse stock split of the issued and outstanding shares of the company's common stock, par value $0.0001 per share, at a ratio of 1-for-40, expected to become effective at 5:00 p.m. ET on August 16. The company's common stock is expected to begin trading on a split-adjusted basis commencing upon market open on August 19. As a result of the reverse stock split, every 40 shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock. The company's Class A common stock will trade under a new CUSIP number, 307359 885, effective August 19, and remain listed on Nasdaq under the symbol "FFIE." The company's Class B common stock will have a new CUSIP number, 307359 877, effective August 19. The company's publicly traded warrants will continue to be traded on the Nasdaq Capital Market under the symbol "FFIEW" and the CUSIP number for the warrants will remain unchanged. For the Company's warrants trading under the symbol "FFIEW", every 40 warrants will be exercisable for one share of Class A common stock at an exercise price of $110,400 per share of Class A common stock. In addition, the authorized shares of common stock will be reduced from 4,169,812,500 to 104,245,313. The reverse stock split impacts all holders of the company's common stock proportionally and will not impact any stockholder's percentage ownership of the company's common stock.

05:11 EDT Leidos receives EU Standard 2.1 certification for Pro:Vision - Leidos has received the EU Standard 2.1 certification for its Pro:Vision three people screening system from the European Civil Aviation Conference, or ECAC. The ECAC Common Evaluation Process, or CEP, of Security Equipment Certification for Security Scanners, or SSc, is a globally recognized, and often required, certification to sell and operate these types of security devices within the European Union.

05:02 EDT Interactive Brokers expands overnight trading offering - Interactive Brokers announced the expansion of its overnight trading offering to include Contracts for Difference, or CFDs, on U.S. stocks and ETFs. In addition to U.S. Stocks, ETFs, and Index Options, this expansion allows clients to trade CFDs on US equities around the clock, five days a week.